SEC Form 4 · accession 0001708138-18-000022
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph L Goldstein
Director
Period of report
Sep 24, 2018
Accepted (ET)
Sep 25, 2018 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 24, 2018 | M | 1,000 | $273.67 | A | 13,000 | D | |
| Common Stock | Sep 24, 2018 | S | 1,000 | $390.00 | D | 12,000 | D | |
| Common Stock | Sep 24, 2018 | M | 1,000 | $273.67 | A | 13,000 | D | |
| Common Stock | Sep 24, 2018 | S | 1,000 | $387.29 | D | 12,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $273.67 | Sep 24, 2018 | M | 1,000 | D | — | Jan 2, 2024 | Common Stock | 1,000 | 5,500 | D |
| Non-Qualified Stock Option (right to buy)F2 | $273.67 | Sep 24, 2018 | M | 1,000 | D | — | Jan 2, 2024 | Common Stock | 1,000 | 4,500 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.